Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "IPCA-Laboratories"

14 News Found

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)
People | October 16, 2023

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)

He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company

Ipca to acquire 33.4% stake in Unichem Labs for Rs 1,034 Cr
News | April 25, 2023

Ipca to acquire 33.4% stake in Unichem Labs for Rs 1,034 Cr

The business and product range of Ipca and that of Unichem complements each others business and product range

Ipca acquires further 6.53% of equity share of Trophic Wellness
News | December 20, 2022

Ipca acquires further 6.53% of equity share of Trophic Wellness

Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.

IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr
News | May 29, 2021

IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr

The company has posted net profit of Rs.1140.01 crores during FY 2020-21

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging